ACOG committee opinion. Breast--ovarian cancer screening. Number 176, October 1996. Committee on Genetics. The American College of Obstetricians and Gynecologists.
出版信息
Int J Gynaecol Obstet. 1997 Jan;56(1):82-3.
PMID:9049704
Abstract
摘要
相似文献
1
ACOG committee opinion. Breast--ovarian cancer screening. Number 176, October 1996. Committee on Genetics. The American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet. 1997 Jan;56(1):82-3.
2
ACOG committee opinion. Breast-ovarian cancer screening. Number 239, August 2000. American College of Obstetricians and Gynecologists. Committee on genetics.
Int J Gynaecol Obstet. 2001 Dec;75(3):339-40.
3
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.对斯德哥尔摩地区乳腺癌和乳腺癌-卵巢癌家族进行的BRCA1基因突变筛查。
Cancer Res. 1997 Jun 15;57(12):2474-7.
4
5
Familial breast and ovarian cancers.家族性乳腺癌和卵巢癌。
Int J Clin Oncol. 2004 Aug;9(4):270-82. doi: 10.1007/s10147-004-0423-3.
6
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.一名乳腺癌和卵巢癌患者的BRCA1和BRCA2基因种系突变
Gynecol Oncol. 1998 Sep;70(3):432-4. doi: 10.1006/gyno.1998.5081.
7
BRCA testing: ethics lessons for the new genetics.BRCA检测：新遗传学的伦理教训
Clin Invest Med. 2004 Feb;27(1):19-22.
8
Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.BRCA1和BRCA2种系突变的双杂合子的表型表达。
J Med Genet. 2005 Mar;42(3):e20. doi: 10.1136/jmg.2004.027243.
9
Laboratory identification of hereditary risk of breast and ovarian cancer.乳腺癌和卵巢癌遗传风险的实验室鉴定
Curr Opin Biotechnol. 1999 Jun;10(3):289-94. doi: 10.1016/S0958-1669(99)80051-2.
Zotero 插件